全基因组CRISPR筛选揭示N-糖基化是CALR突变型骨髓增殖性肿瘤的遗传和治疗脆弱性
研究对突变CALR转化的造血细胞进行全基因组CRISPR敲除筛选,发现N-糖基化通路基因差异耗竭;药物抑制N-糖基化通过降低MPL细胞表面表达 impair 突变细胞生长;2-DG在Calr突变敲入小鼠中显示优先敏感性并改善MPN疾病特征;患者来源CALR突变骨髓CFU-MK形成显著减少。
要点
- 全基因组CRISPR筛选发现N-糖基化通路在突变CALR转化细胞中差异耗竭。
- 化学抑制N-糖基化通过降低MPL细胞表面表达损害突变CALR转化细胞生长。
- 2-DG在Calr突变敲入小鼠中显示优先敏感性并改善关键MPN疾病特征。
核心结论
- 研究结果推进了CALR突变型MPN克隆选择性治疗的开发。
研究设计与样本
- 在突变CALR转化的造血细胞中进行全基因组CRISPR敲除耗竭筛选。
- 针对CRISPR筛选发现的独特脆弱性进行聚焦药物体外筛选。
- 使用Calr突变敲入小鼠进行2-DG治疗。
- 在患者来源CALR突变骨髓与健康供者骨髓中进行巨核细胞集落形成单位(CFU-MK)检测。
主要发现
- N-糖基化通路基因在突变CALR转化细胞中较对照细胞差异耗竭。
- 化学抑制N-糖基化通过降低MPL细胞表面表达损害突变CALR转化细胞生长。
- Calr突变敲入小鼠中Calr突变细胞对2-DG的敏感性高于野生型细胞,并实现关键MPN疾病特征正常化。
- N-糖基化抑制显著减少患者来源CALR突变骨髓的CFU-MK形成,较健康供者骨髓相比。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Calreticulin (CALR) mutations are frequent, disease-initiating events in myeloproliferative neoplasms (MPNs). Although the biological mechanism by which CALR mutations cause MPNs has been elucidated, there currently are no clonally selective therapies for CALR-mutant MPNs. To identify unique genetic dependencies in CALR-mutant MPNs, we performed a whole-genome clustered regularly interspaced short palindromic repeats (CRISPR) knockout depletion screen in mutant CALR-transformed hematopoietic cells. We found that genes in the N-glycosylation pathway (among others) were differentially depleted in mutant CALR-transformed cells as compared with control cells. Using a focused pharmacological in vitro screen targeting unique vulnerabilities uncovered in the CRISPR screen, we found that chemical inhibition of N-glycosylation impaired the growth of mutant CALR-transformed cells, through a reduction in MPL cell surface expression. We treated Calr-mutant knockin mice with the N-glycosylation inhibitor 2-deoxy-glucose (2-DG) and found a preferential sensitivity of Calr-mutant cells to 2-DG as compared with wild-type cells and normalization of key MPNs disease features. To validate our findings in primary human cells, we performed megakaryocyte colony-forming unit (CFU-MK) assays. We found that N-glycosylation inhibition significantly reduced CFU-MK formation in patient-derived CALR-mutant bone marrow as compared with bone marrow derived from healthy donors. In aggregate, our findings advance the development of clonally selective treatments for CALR-mutant MPNs.
引用
- Jutzi JS, Marneth AE, Ciboddo M, et al. Whole-genome CRISPR screening identifies N-glycosylation as a genetic and therapeutic vulnerability in CALR-mutant MPNs. Blood. 2022. PMID: 35763665. doi:10.1182/blood.2022015629
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。